Incremental Cost-effectiveness Thresholds for Policy Decision-makers: Is ICER the Most Appropriate Measure to Use?
作者信息
Al Sabahi Sultana, Almasharfi Ahmed
机构信息
Directorate General of Planning and Studies, Ministry of Health, Muscat, Oman.
Diwan Medical Service, Muscat, Oman.
出版信息
Oman Med J. 2024 Jan 31;39(1):e603. doi: 10.5001/omj.2024.40. eCollection 2024 Jan.
Abstract
摘要
相似文献
1
Incremental Cost-effectiveness Thresholds for Policy Decision-makers: Is ICER the Most Appropriate Measure to Use?
Oman Med J. 2024 Jan 31;39(1):e603. doi: 10.5001/omj.2024.40. eCollection 2024 Jan.
2
Use of the incremental cost-effectiveness ratio for decision-making policies-what is the problem? A perspective paper.
Expert Rev Pharmacoecon Outcomes Res. 2022 Sep;22(6):913-918. doi: 10.1080/14737167.2022.2064847. Epub 2022 May 5.
3
Evaluation of the National Institute for Health and Care Excellence Diagnostics Assessment Program Decisions: Incremental Cost-Effectiveness Ratio Thresholds and Decision-Modifying Factors.
Value Health. 2020 Oct;23(10):1300-1306. doi: 10.1016/j.jval.2020.04.1835. Epub 2020 Aug 18.
4
Identifying a Single Optimal Integrated Cervical Cancer Prevention Policy in Norway: A Cost-Effectiveness Analysis.
Med Decis Making. 2022 Aug;42(6):795-807. doi: 10.1177/0272989X221082683. Epub 2022 Mar 8.
5
A theory on ICER pricing and optimal levels of cost-effectiveness thresholds: a bargaining approach.
Front Health Serv. 2023 Aug 24;3:1055471. doi: 10.3389/frhs.2023.1055471. eCollection 2023.
6
Applying the net-benefit framework for assessing cost-effectiveness of interventions towards universal health coverage.
Cost Eff Resour Alloc. 2012 Jul 16;10(1):8. doi: 10.1186/1478-7547-10-8.
7
Information created to evade reality (ICER): things we should not look to for answers.
Pharmacoeconomics. 2006;24(11):1121-31. doi: 10.2165/00019053-200624110-00008.
8
Systematic overview of cost-effectiveness thresholds in ten countries across four continents.
J Comp Eff Res. 2015 Sep;4(5):485-504. doi: 10.2217/cer.15.38.
9
Cost-effectiveness and budget impact of the community-based management of hypertension in Nepal study (COBIN): a retrospective analysis.
Lancet Glob Health. 2019 Oct;7(10):e1367-e1374. doi: 10.1016/S2214-109X(19)30338-9.
10
Active Tuberculosis Screening via a Mobile Health App in Myanmar: Incremental Cost-Effectiveness Evaluation.
JMIR Form Res. 2023 Nov 10;7:e51998. doi: 10.2196/51998.
本文引用的文献
1
Incremental Cost-effectiveness Thresholds for Policy Decision-makers.
Oman Med J. 2022 Sep 30;37(5):e413. doi: 10.5001/omj.2022.106. eCollection 2022 Sep.
2
Calculating and Interpreting ICERs and Net Benefit.
Pharmacoeconomics. 2020 Aug;38(8):785-807. doi: 10.1007/s40273-020-00914-6.
3
Why it's Time to Abandon the ICER.
Pharmacoeconomics. 2020 Aug;38(8):781-784. doi: 10.1007/s40273-020-00915-5.
4
Applying the net-benefit framework for assessing cost-effectiveness of interventions towards universal health coverage.
Cost Eff Resour Alloc. 2012 Jul 16;10(1):8. doi: 10.1186/1478-7547-10-8.
5
Advantages of using the net-benefit approach for analysing uncertainty in economic evaluation studies.
Pharmacoeconomics. 2003;21(1):39-48. doi: 10.2165/00019053-200321010-00003.
Zotero 插件